On September 21, ALI HEALTH fell 5.38% in regular trading, trading at HK$2.9/share, with turnover of HK$132 million. The decline was triggered by CICC issuing a research note on the same day that sharply cut the company's target price by 30.8% to HK$4.5 based on a Sum-of-the-Parts valuation, while maintaining an Outperform rating.

CICC lowered its FY2027 and FY2028 non-GAAP net profit forecasts by 6.6% and 5.8% to RMB 2.178 billion and RMB 2.421 billion respectively, citing volatility in the health supplement category, regulatory sentiment overhang on the supplements industry during Q2 FY2027, and uncertainty around the pace of the company's medical AI investment. Adding to headwinds, ALI HEALTH was removed from the Hang Seng TECH 100 Index effective September 14, as the index rebalanced toward AI and hard-tech names. UBS Group AG has also been continuously trimming its stake, with its long position declining to 7.96%. Meanwhile, the company underwent a leadership transition on September 11, with Yu Yong succeeding Shen Difan as Chairman and CEO. Multiple negative factors converging have placed clear pressure on the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)